Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 27,423 Shares

Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) insider Robert Berman sold 27,423 shares of Biohaven Pharmaceutical Holding Co stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $26.60, for a total transaction of $729,451.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Robert Berman also recently made the following trade(s):

  • On Tuesday, November 14th, Robert Berman sold 160,000 shares of Biohaven Pharmaceutical Holding Co stock. The stock was sold at an average price of $25.76, for a total transaction of $4,121,600.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN) traded down $1.00 during trading hours on Tuesday, hitting $24.39. 326,430 shares of the stock traded hands, compared to its average volume of 225,220. Biohaven Pharmaceutical Holding Co Ltd has a twelve month low of $17.00 and a twelve month high of $39.51.

WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Robert Berman Sells 27,423 Shares” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://transcriptdaily.com/2017/11/15/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-robert-berman-sells-27423-shares.html.

A number of research analysts recently issued reports on the stock. BidaskClub downgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “strong sell” rating in a research note on Tuesday. William Blair reiterated an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, October 3rd. Piper Jaffray Companies reiterated a “buy” rating and issued a $54.00 price target on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. Zacks Investment Research upgraded shares of Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, Needham & Company LLC decreased their price target on shares of Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Biohaven Pharmaceutical Holding Co has an average rating of “Buy” and a consensus price target of $40.80.

Large investors have recently modified their holdings of the company. Deschutes Portfolio Strategy LLC purchased a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $374,000. Strs Ohio purchased a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $680,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $7,483,000. Emerald Advisers Inc. PA purchased a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $9,096,000. Finally, Alps Advisors Inc. purchased a new stake in shares of Biohaven Pharmaceutical Holding Co during the 3rd quarter worth approximately $1,316,000.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply